Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer

[1] Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-E386

[2] Soerjomataram I(2013)Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry Gastric Cancer 16 1-27

[3] Dikshit R(2013)Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East Dig Surg 30 119-129

[4] Eser S(2011)Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer J Clin Oncol 29 4387-4393

[5] Mathers C(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820

[6] Rebelo M(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221

[7] Nashimoto A(2006)Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991-4997

[8] Akazawa K(1995)Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination Semin Oncol 22 3-16

[9] Isobe Y(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548-557

[10] Miyashiro I(2002)Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells Eur J Cancer 38 1271-1277

[1] Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-E386

[2] Soerjomataram I(2013)Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry Gastric Cancer 16 1-27

[3] Dikshit R(2013)Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East Dig Surg 30 119-129

[4] Eser S(2011)Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer J Clin Oncol 29 4387-4393

[5] Mathers C(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820

[6] Rebelo M(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221

[7] Nashimoto A(2006)Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991-4997

[8] Akazawa K(1995)Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination Semin Oncol 22 3-16

[9] Isobe Y(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548-557

[10] Miyashiro I(2002)Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells Eur J Cancer 38 1271-1277